Vanda Pharmaceuticals, Inc. (VNDA), a Washington-based biopharmaceutical company, Monday said tasimelteon, a compound under trial for the treatment in totally blind individuals, suffering from Non-24-Hour disorder, is found to restore daily cortisol rhythms.
Non-24 disorder occurs mostly in totally blind people. This puts the people under pressure as circadian rhythms which guide many of the body's functions, including sleep, hormone rhythms and metabolism are not reset to a regular 24-hour cycle. Individuals with Non-24 are unable to synchronize their internal clock to the 24-hour day-night cycle, which disrupts their sleep-wake cycle.
Through its RESET, a phase III study, Non-24 patients were given a 20 mg dose of tasimelteon daily for 6 weeks and subsequent results showed tasimelteon was able to reset the master body clock and was found well-suited to perform as a circadian regulator.
On Friday, the company's shares closed at $4.00 on the NASDAQ.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.